369 related articles for article (PubMed ID: 27307412)
1. Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.
Davis CC; Zelnak A; Eley JW; Goldstein DA; Switchenko JM; McKibbin T
Ann Pharmacother; 2016 Sep; 50(9):712-7. PubMed ID: 27307412
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
3. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
5. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
6. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
8. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
[TBL] [Abstract][Full Text] [Related]
9. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
10. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Banke A; Fosbøl EL; Ewertz M; Videbæk L; Dahl JS; Poulsen MK; Cold S; Jensen MB; Gislason GH; Schou M; Møller JE
JACC Heart Fail; 2019 Mar; 7(3):217-224. PubMed ID: 30819377
[TBL] [Abstract][Full Text] [Related]
12. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital.
Ayres LR; de Almeida Campos MS; de Oliveira Gozzo T; Martinez EZ; Ungari AQ; de Andrade JM; Pereira LR
Int J Clin Pharm; 2015 Apr; 37(2):365-72. PubMed ID: 25637407
[TBL] [Abstract][Full Text] [Related]
14. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab.
De Sanctis R; Giordano L; D'Antonio F; Agostinetto E; Marinello A; Guiducci D; Masci G; Losurdo A; Zuradelli M; Torrisi R; Santoro A
Breast; 2021 Jun; 57():80-85. PubMed ID: 33780903
[TBL] [Abstract][Full Text] [Related]
16. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.
Yu AF; Yadav NU; Lung BY; Eaton AA; Thaler HT; Hudis CA; Dang CT; Steingart RM
Breast Cancer Res Treat; 2015 Jan; 149(2):489-95. PubMed ID: 25552363
[TBL] [Abstract][Full Text] [Related]
18. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
Long HD; Lin YE; Zhang JJ; Zhong WZ; Zheng RN
Oncologist; 2016 May; 21(5):547-54. PubMed ID: 27026675
[TBL] [Abstract][Full Text] [Related]
19. Cardiac monitoring during trastuzumab therapy in metastatic breast cancer: early incidence of cardiac dysfunction.
Perone F; Zamora Auñon P; Rodríguez L; Vinal D; Caro-Codon J; Pertejo A; Martínez Marín V; Espinosa E; López-Fernández T
Monaldi Arch Chest Dis; 2022 Feb; 92(4):. PubMed ID: 35179011
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
